VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
NAMs represent a shift away from traditional animal models toward human-relevant in vitro and ex vivo systems. VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates (ADCs), and bispecific antibody-drug conjugates (bsADCs). This aligns with broader regulatory momentum: the FDA has been encouraging the adoption of NAMs to improve the predictive validity of preclinical studies and reduce reliance on animal testing.
The company reported that its lead BiTAC-TCE and bsADC candidates were evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
For investors and industry observers, the update signals potential cost and time efficiencies in drug development. By cutting the number of animals required and shortening preclinical cycles, VERAXA may bring therapies to clinical trials faster and at lower cost. This could improve the company’s competitive position in the crowded oncology space, where speed and capital efficiency are critical. For patients, the use of human-derived models might yield more predictive data, potentially increasing the odds of clinical success.
The announcement also reflects a growing trend in biotech: regulators, investors, and the public are increasingly focused on ethical and human-relevant research methods. VERAXA’s progress with NAMs could serve as a case study for other companies seeking to align with FDA guidance. As the FDA continues to evaluate NAMs, early adopters may benefit from smoother regulatory interactions and enhanced reputation among stakeholders.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). Its BiTAC format is a registered trademark of VERAXA Biotech GmbH. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
The full press release is available at https://ibn.fm/9YRJw, and the original release can be viewed on www.newmediawire.com. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Undue reliance should not be placed on these statements when making an investment decision.
